Background: Real-world evidence (RWE) can provide postmarket data to inform whether
funded cancer drugs yield expected outcomes and value for money, but it is unclear how to …

Canadian provinces routinely collect patient-level data for administrative purposes. These
real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical …

Background Oncology therapy is becoming increasingly more expensive and challenging
the affordability and sustainability of drug programmes around the world. When new drugs …

Aim: This study explored the perceived value of real-world evidence (RWE) in the
reassessment of oncology therapies by collecting the perspectives of health technology …

BACKGROUND: Randomized controlled trials (RCTs), the gold standard of safety and
efficacy evidence, are conducted in select patients that may not mirror real-world …

The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration
was established to develop a framework for generating and using real-world evidence …

The CanREValue Collaboration established the Reassessment & Uptake Working Group to
develop a preliminary process to reassess funded cancer drugs in Canada. A simulated …

Real-world evidence (RWE) can provide insights into patient profiles, disease detection,
treatment choice, dosing strategies, treatment sequencing, adverse event management and …

The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
developed an MCDA rating tool to assess and prioritize potential post-market real-world …

Objectives This study aimed to describe the role of real-world data (RWD) and real-world
evidence (RWE) in health technology assessment (HTA) in 5 European countries and to …